Johnson & Johnson (NYSE:JNJ) diabetes company Calibra Medical touted research data from patients using its OneTouch Via on-demand insulin delivery system which indicated less missed insulin doses and lowered stress about dosing.
The OneTouch Via device is an in-development wearable, on-demand insulin delivery system designed to deliver rapid-acting insulin at mealtimes, the company said.
“People with diabetes can often feel embarrassment or discomfort when they need to inject insulin at mealtimes or when snacking. In a social situation, they may choose to miss a dose so they don’t have to take themselves out of the moment, but avoiding needed insulin doses may lead to serious health complications over time. Because patients in the study were empowered to dose discreetly with the OneTouch Via, they felt encouraged to dose more often – and ultimately, they reported missing fewer doses and better adherence to their treatment regimen,” Lifescan chief medical officer Dr. Brian Levy said in prepared remarks.
Results from the company’s 44-patient MAE study also reported that physicians were more likely to recommend the OneTouch device to patients who are not at A1C goals or who are new to rapid-acting insulin therapy, the company said.
The Mae study evaluated patients with a median age of 57 years who used the OneTouch Via patch for 60 days, and reported 52% of patients said they were dosing more often than they would with a pen or syringe. A total 98% of patients said the patch allowed them to dose more discreetly in public, with 99% saying they were less worried about forgetting insulin.
“We understand the physical and emotional challenges people with diabetes face every day, and are constantly driving to create innovative solutions that help people with diabetes manage their condition and live the life they want. As an injection-free insulin delivery patch, OneTouch Via will help people stay on top of their treatment and also allow them to stay in those vital moments in life – a dinner party, a grandchild’s birthday, a work event. It is our hope that once commercially available, it will eliminate the barriers many people living with diabetes face surrounding mealtime insulin and ultimately improve health outcomes,” Animas Corp insulin delivery veep John Wilson said in a press release.